Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical Limited announced that its drug TQB2102, a HER2 bispecific antibody-drug conjugate, has been included in China’s Breakthrough Therapeutic Designation process. This inclusion is expected to expedite the drug’s approval, offering a promising treatment for HER2 IHC 3+ advanced colorectal cancer, a condition with limited effective treatment options. The drug has shown a 34.8% objective response rate in clinical trials, indicating significant potential to improve patient outcomes in a field where current therapies have limited efficacy.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the development and commercialization of pharmaceutical products. The company is involved in creating innovative drugs, particularly in the oncology sector, and operates with a market focus on China.
YTD Price Performance: 147.15%
Average Trading Volume: 160,441,487
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.5B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.